Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05404711 · ClinicalTrials.gov registry record · NA

Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation

A NA study of Insulin Resistance and Overweight and Obesity, sponsored by Mary Ellen Vajravelu, MD.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05404711 is a NA study of Insulin Resistance and Overweight and Obesity that has completed, run by Mary Ellen Vajravelu, MD. The registered enrollment target is 40 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05404711, a NA study of Insulin Resistance and Overweight and Obesity, has completed, sponsored by Mary Ellen Vajravelu, MD.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose tolerance test (OGTT). This study will involve wearing a CGM, wearing a physical activity tracker, responding to surveys, and completing at-home glucose and mixed food challenge while wearing the CGM. Subjects will also be asked to complete an interview by phone or videoconference after wearing the CGM.

Interventions

  • DEVICE CGM

Study Locations (1)

Pennsylvania

  • Children's Hospital of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-10-11
Est. Completion 2023-12-14
Phase NA

Sponsor

Mary Ellen Vajravelu, MD

1 total trials

What the Registry Record Tells You About NCT05404711

The ClinicalTrials.gov registry entry for NCT05404711 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (84% lower). The listed sponsor is Mary Ellen Vajravelu, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which CGM is the first listed.

NCT05404711 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05404711 about?

NCT05404711 is a clinical study titled "Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation". The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose tolerance test (OGTT). This study will involve wearing a CGM, wearing a ph...

What is the current status of trial NCT05404711?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2022-10-11. Estimated completion is 2023-12-14.

What conditions does trial NCT05404711 study?

This clinical trial studies the following conditions: Insulin Resistance, Overweight and Obesity, PreDiabetes.

What interventions are being tested in trial NCT05404711?

The interventions under investigation include: CGM (DEVICE).

Who is sponsoring clinical trial NCT05404711?

This trial is sponsored by Mary Ellen Vajravelu, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05404711 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.